Patient-Reported Outcome in Metastatic Breast Cancer and Platinum-Resistant Recurrent Ovarian Cancer Patients Treated with Metronomic Cyclophosphamide ± Methotrexate: PROmetronomic
MCT had no significant impact on HRQoL of our small cohort of heavily pretreated MBC and ROC patients and may represent a valuable treatment option for maintaining HRQoL in selected patients.
Authors
- Anne-Sophie Heimes (ORCID: https://orcid.org/0000-0001-5472-5224)
- Timo Schinköthe (ORCID: https://orcid.org/0000-0002-2008-6775)
- Annette Hasenburg (ORCID: https://orcid.org/0000-0002-1547-4968)
- Ina Shehaj (ORCID: https://orcid.org/0009-0001-3304-5040)
- Walburgis Brenner (ORCID: https://orcid.org/0000-0002-1511-6212)
- Slavomir Krajnak (ORCID: https://orcid.org/0000-0002-8012-5772)
- Marcus Schmidt (ORCID: https://orcid.org/0000-0003-1365-2414)
- Marco Johannes Battista (ORCID: https://orcid.org/0000-0003-2363-5001)
Institutions
- Goethe University Frankfurt (DE)
- Johannes Gutenberg University Mainz (DE)
- Universität der Bundeswehr München (DE)
- Diakonie Klinikum Jung-Stilling (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1159/000547766
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00